In 2022, in partnership with many other organizations, CGA-IGC advocated for the USPSTF to consider a topic review for Lynch Syndrome Risk Assessment. We succeeded, and the USPSTF has drafted a research plan open to public comment until MARCH 1ST, 2023, 11:59 PM EST.
This is a potential game-changer given that all USPSTF Grade A/B recommendations are required to be covered by payors with NO COST SHARING to the patient. That means NO co-payment, NO deductible, NO out-of-pocket expense. This designation has the potential to significantly expand access to genomics services, dismantle barriers, and narrow disparities in genetic counseling and genetic testing.
CGA-IGC will be entering detailed comments as an organization, and we encourage all individuals and organizations to do the same. Our collective voice is POWERFUL.
Thank you for your consideration.
Of note, the USPSTF previously reviewed BRCA-related Cancer in 2019 can be used as a reference for the potential end product if this research plan moves forward.
Comments